Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 277

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 277
---
 was later extended to June
2023 following an agreement between the Company and the 2020 CLA investors dated December 2022). In October 2021, the Company and 2020
CLA investors reached an agreement according to which, in connection with the raising of the 2021 Notes, the 2020 Notes shall be converted
into ordinary shares of the Company upon the occurrence of an exit event (including an IPO or merger,) of the Company based on a price
per share equal to 80% at a pre money valuation of $5,150.

On January 3, 2024, the Company extended
the due date until April 30, 2024 and, subsequently on April 26, 2024 further extended the due date until May 27, 2024. In October 2024,
the Company signed an addendum to the 2020 CLA agreement (see also Note 14).

The Company estimates the fair value
of the 2020 Notes using the Probability-Weighted Expected Return Method (PWERM). For years ended December 31, 2023, and 2022, the Company
recorded an expense of $1,951 and $205 for the revaluation of such 2020 Notes, within financial expense, net in the statements of comprehensive
loss.

<div align='center'>F-30</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 6:- | CONVERTIBLE NOTES (Cont.) |

A summary of significant unobservable
inputs (Level 3 inputs) used in measuring the fair value of 2020 Notes outstanding are as follows:

|                  |     |   | December 31, 
         2023 |   |     |   | December 31, 
         2022 |   |
|:-----------------|:----|:--|-------------:|:--|:----|:--|-------------:|:--|
| Principal amount |     | $ |          900 |   |     | $ |          900 |   |
| Discount rate    |     |   |         30.0 | % |     |   |         30.0 | % |
| Term (years)     |     |   |         0.25 |   |     |   |          0.5 |   |
| Fair value